Circulating Tumor Cells and Personalized Medicine

Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional ‘solid biopsy’, which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.

Download Full-text

EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis

Cancers ◽

10.3390/cancers12061632 ◽

2020 ◽

Vol 12 (6) ◽

pp. 1632 ◽

Cited By ~ 8

Author(s):

Anthony Genna ◽

Aline M. Vanwynsberghe ◽

Amélie V. Villard ◽

Charles Pottier ◽

Julien Ancel ◽

...

Keyword(s):

Personalized Medicine ◽

Cancer Patient ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Crucial Role ◽

Patient Management ◽

The Road ◽

Metastatic Colonization ◽

On The Road ◽

Early Phases

Epithelial–mesenchymal transitions (EMTs) generate hybrid phenotypes with an enhanced ability to adapt to diverse microenvironments encountered during the metastatic spread. Accordingly, EMTs play a crucial role in the biology of circulating tumor cells (CTCs) and contribute to their heterogeneity. Here, we review major EMT-driven properties that may help hybrid Epithelial/Mesenchymal CTCs to survive in the bloodstream and accomplish early phases of metastatic colonization. We then discuss how interrogating EMT in CTCs as a companion biomarker could help refine cancer patient management, further supporting the relevance of CTCs in personalized medicine.

Download Full-text

Personalized Medicine through Circulating Tumor Cells: The New Dimension in Cancer Research

Journal of Developing Drugs ◽

10.4172/2329-6631.1000e128 ◽

2013 ◽

Vol 02 (03) ◽

Author(s):

Shailender Singh Kanwar

Keyword(s):

Cancer Research ◽

Personalized Medicine ◽

Tumor Cells ◽

Circulating Tumor Cells

Download Full-text

Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms

Endocrine Related Cancer ◽

10.1530/erc-17-0091 ◽

2017 ◽

Vol 24 (6) ◽

pp. R223-R237 ◽

Cited By ~ 18

Author(s):

Maria Chiara Zatelli ◽

Erika Maria Grossrubatscher ◽

Elia Guadagno ◽

Concetta Sciammarella ◽

Antongiulio Faggiano ◽

...

Keyword(s):

Prognostic Factors ◽

Personalized Medicine ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Resource Utilization ◽

Clinical Management ◽

Prognostic Markers ◽

Neuroendocrine Neoplasms

The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking advantage of the most modern techniques, in the perspective of personalized medicine and appropriate resource utilization. This review summarizes the available data on the possible role of circulating tumor cells and microRNAs as prognostic markers in NENs.

Download Full-text